{"id":"tafenoquine","rwe":[{"pmid":"41849481","year":"2026","title":"[Expansion of the use of technologies to reduce cases of malaria due to Plasmodium vivax in the Brazilian Amazon: a budget impact analysis].","finding":"","journal":"Cadernos de saude publica","studyType":"Clinical Study"},{"pmid":"41737900","year":"2025","title":"Strategic resource allocation for malaria elimination in endemic settings: a systematic review of cost-effectiveness evidence.","finding":"","journal":"Frontiers in public health","studyType":"Clinical Study"},{"pmid":"41717344","year":"2026","title":"Resolving haplotypes of the glucose-6-phosphate dehydrogenase gene using long-range polymerase chain reaction and Oxford Nanopore sequencing.","finding":"","journal":"Biology methods & protocols","studyType":"Clinical Study"},{"pmid":"41696711","year":"2026","title":"Plasmodium falciparum field isolates drug susceptibility in Mali.","finding":"","journal":"JAC-antimicrobial resistance","studyType":"Clinical Study"},{"pmid":"41690325","year":"2026","title":"Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial.","finding":"","journal":"The Lancet. Infectious diseases","studyType":"Clinical Study"}],"_fda":{"id":"661ad23b-4c46-4122-9f6c-06feeb80d95a","risks":["Risk Summary The use of ARAKODA during pregnancy may cause hemolytic anemia in a fetus who is G6PD-deficient. Treatment with ARAKODA during pregnancy is not recommended. If a pregnancy is detected during ARAKODA use, discontinue ARAKODA as soon as possible and switch to an alternative prophylactic drug for malaria during pregnancy [see Warnings and Precautions ( 5.2 )] . Available data with use of ARAKODA in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal studies, there were increased abortions, with and without maternal toxicity when tafenoquine was given orally to pregnant rabbits at and above doses equivalent to about 0.4 times the clinical exposure based on body surface area comparisons. No fetotoxicity was observed at doses about 1.5 times the clinical exposure (based on body surface area comparisons) in a similar study in rats. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.","Risk Summary A breastfed infant with G6PD deficiency is at risk for hemolytic anemia from exposure to ARAKODA. Infant G6PD status should be checked before breastfeeding begins. ARAKODA is contraindicated in breastfeeding women when the infant is found to be G6PD deficient or the G6PD status of the infant is unknown [see Contraindications ( 4 ) and Clinical Considerations ] . There is no information regarding the presence of ARAKODA in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. In a breastfed infant with normal G6PD, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ARAKODA and any potential effects on the breastfed infant from ARAKODA or from the underlying maternal condition."],"set_id":"299e49d8-470f-4779-a010-4a1ee0e0c6cd","openfda":{"unii":["262P8GS9L9"],"route":["ORAL"],"rxcui":["2054096","2054102"],"spl_id":["661ad23b-4c46-4122-9f6c-06feeb80d95a"],"brand_name":["Arakoda"],"spl_set_id":["299e49d8-470f-4779-a010-4a1ee0e0c6cd"],"package_ndc":["71475-257-01","71475-257-02"],"product_ndc":["71475-257"],"generic_name":["TAFENOQUINE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["TAFENOQUINE"],"manufacturer_name":["60 Degrees Pharmaceuticals, INC."],"application_number":["NDA210607"],"is_original_packager":[true]},"version":"6","pregnancy":["8.1 Pregnancy Risk Summary The use of ARAKODA during pregnancy may cause hemolytic anemia in a fetus who is G6PD-deficient. Treatment with ARAKODA during pregnancy is not recommended. If a pregnancy is detected during ARAKODA use, discontinue ARAKODA as soon as possible and switch to an alternative prophylactic drug for malaria during pregnancy [see Warnings and Precautions ( 5.2 )] . Available data with use of ARAKODA in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal studies, there were increased abortions, with and without maternal toxicity when tafenoquine was given orally to pregnant rabbits at and above doses equivalent to about 0.4 times the clinical exposure based on body surface area comparisons. No fetotoxicity was observed at doses about 1.5 times the clinical exposure (based on body surface area comparisons) in a similar study in rats. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk: Malaria during pregnancy increases the risk for adverse pregnancy outcomes, including maternal anemia, prematurity, spontaneous abortion and stillbirth. Data Animal Data: Tafenoquine resulted in dose-related abortions when given orally to pregnant rabbits during organogenesis (Gestation Days 6 to 18), at doses of 7 mg/kg (about 0.4 times the clinical exposure based on body surface area comparisons) and above. Doses higher than 7 mg/kg were also associated with maternal toxicity (mortality and reduced body weight gain). In a similar study in rats, doses of 3, 10, or 30 mg/kg/day resulted in maternal toxicity (enlarged spleen, reduced body weight and reduced food intake) but no fetotoxicity at the high dose (about 1.5 times the clinical exposure based on body surface area comparisons). There was no evidence of malformations in either species. In a pre- and postnatal development study in rats, tafenoquine administered throughout pregnancy and lactation produced maternal toxicity and a reversible decrease in offspring body weight gain and decrease in motor activity at 18 mg/kg/day, which is equivalent to about 0.6 times the clinical dose based on body surface area comparisons."],"overdosage":["10 OVERDOSAGE There were no reported cases of ARAKODA overdose. Hemoglobin decline and methemoglobinemia may be encountered in an overdose with ARAKODA. Treatment of overdosage consists of institution of appropriate symptomatic and/or supportive therapy."],"description":["11 DESCRIPTION ARAKODA contains tafenoquine succinate, an antimalarial agent for oral administration. The structural formula of tafenoquine succinate is: Figure 1: Tafenoquine Succinate Structure The chemical name of tafenoquine succinate is (±)-8-[(4-amino-1-methylbutyl) amino]-2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl) phenoxy]quinoline succinate. The molecular formula of tafenoquine succinate is C 24 H 28 F 3 N 3 O 3 ∙C 4 H 6 O 4 and its molecular weight is 581.6 as the succinate salt (463.49 as free base). Each ARAKODA tablet contains 100 mg of tafenoquine (equivalent to 125.5 mg of tafenoquine succinate). Inactive ingredients include magnesium stearate, mannitol, and microcrystalline cellulose. The tablet film coating inactive ingredients include: hypromellose, iron oxide red, macrogol/polyethylene glycol and titanium dioxide. Figure 1: Tafenoquine Succinate Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied ARAKODA tablets contain 100 mg of tafenoquine (equivalent to 125.5 mg of tafenoquine succinate) and are dark pink, film-coated, capsule-shaped, and debossed with ‘TQ100’ on one side. ARAKODA tablets are packed in blister packs or bottles. For the blister pack presentation, ARAKODA tablets are packed in polyamide aluminum and PVC formable laminate backed blisters with a polyethylene terephthalate aluminum foil cover. Each blister card contains 8 tablets. Each package contains 2 blister cards (16 tablets) housed in a contiguous outer paperboard child-resistant carton component (NDC 71475-257-01). For the bottle presentation, ARAKODA tablets are packed in 40 cc, 33 mm white high-density polyethylene bottles with a 33 mm polypropylene screw-top child resistant cap with an induction seal liner. Each bottle contains 8 tablets (NDC 71475-257-02). Storage Store at less than 30°C (86°F). Protect from moisture. Dispense only in the original carton or bottle."],"microbiology":["12.4 Microbiology Mechanism of Action Tafenoquine, an 8-aminoquinoline antimalarial, is active against all the stages of Plasmodium species that include the hypnozoite (dormant stage) in the liver. Studies in vitro with the erythrocytic forms of Plasmodium falciparum suggest that tafenoquine may exert its effect by inhibiting hematin polymerization and inducing apoptotic like death of the parasite. In addition to its effect on the parasite, tafenoquine causes red blood cell shrinkage in vitro. The molecular target of tafenoquine is not known. Antimicrobial activity Tafenoquine is active against pre-erythrocytic (liver) and erythrocytic (asexual) forms as well as gametocytes of Plasmodium species that include P. falciparum and P. vivax. The activity of tafenoquine against the pre-erythrocytic liver stages of the parasite, prevents the development of the erythrocytic forms of the parasite [see Clinical Studies ( 14 )] . Resistance A potential for development of resistance of Plasmodium species to tafenoquine was not evaluated. Studies with the erythrocytic forms of P. falciparum strains/isolates suggest a potential for cross-resistance with primaquine, an 8-aminoquinoline. Clinical relevance of such findings is not known."],"spl_medguide":["Medication Guide MEDICATION GUIDE ARAKODA (AIR-uh-KOH-duh) (tafenoquine) tablets, for oral use What is the most important information I should know about ARAKODA? ARAKODA can cause serious side effects including : • Breakdown of red blood cells (hemolytic anemia). See “ Do not take ARAKODA if you :” ARAKODA can cause a breakdown of red blood cells (hemolysis) in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Your healthcare provider will test you for G6PD deficiency before you start taking ARAKODA. Signs of hemolytic anemia may not happen right away (delayed reaction).Tell your healthcare provider or get emergency medical help right away if you develop signs of hemolytic anemia which include darkening of the urine, dizziness, confusion, feeling tired, light-headedness, or shortness of breath, pale skin or yellowing of the skin and whites of the eyes. • Decrease of oxygen in your blood caused by a certain type of abnormal red blood cell (methemoglobinemia) . Signs and symptoms of methemoglobinemia may not happen right away (delayed reaction). Get medical help right away if you have bluish coloring of the lips or skin, headache, fatigue, shortness of breath, or lack of energy. • Mental health (psychiatric) symptoms . See “ Do not take ARAKODA if you :” Sleep problems, depression, anxiety and psychosis have happened while taking ARAKODA. Psychiatric symptoms may not happen right away (delayed reaction). Get emergency medical help right away if you develop hallucinations (seeing or hearing things that are really not there), delusions (false or strange thoughts or beliefs), or if you get confused or have problems thinking while taking ARAKODA. Call your healthcare provider if you develop changes in your mood, anxiety, trouble sleeping (insomnia), or nightmares for 3 days or longer while taking ARAKODA. • ARAKODA can have other serious side effects. See “ What are the possible side effects of ARAKODA? ” What is ARAKODA? • ARAKODA is a prescription medicine used to help prevent malaria in people 18 years of age and older. • Malaria is a serious disease of the blood that is spread by infected mosquitos. • It is not known if ARAKODA is safe and effective in children. Do not take ARAKODA if you : • have G6PD deficiency. • are breastfeeding a child known to have G6PD deficiency or breastfeeding a child that has not been tested for G6PD deficiency. • have a history of psychotic disorders, or you currently have psychotic symptoms including hallucinations (seeing or hearing things that are not really there), delusions (false or strange thoughts or beliefs), or disorganized thinking or behavior. • are allergic to tafenoquine, other 8-aminoquinolines, or any of the ingredients in ARAKODA. See the end of this Medication Guide for a complete list of ingredients in ARAKODA. Before taking ARAKODA, tell your health care provider about all your medical conditions, including if you : • have nicotinamide adenine dinucleotide (NADH) reductase deficiency. People with NADH reductase deficiency have a higher risk for methemoglobinemia if they take ARAKODA. • have or have had mental health problems. • are pregnant or plan to become pregnant. ARAKODA can harm an unborn baby who has G6PD deficiency. o You should not become pregnant during treatment with ARAKODA. o Females who are able to become pregnant should use effective birth control (contraception) during treatment with ARAKODA. Talk with your healthcare provider about birth control methods that may be right for you. o Your healthcare provider may suggest you take a pregnancy test before you start taking ARAKODA. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ARAKODA. • are breastfeeding or plan to breastfeed. It is not known if ARAKODA passes into breast milk. See “ Do not take ARAKODA if you :” o Your healthcare provider should check your child for G6PD deficiency before you start breastfeeding. o If you know your child has G6PD deficiency, do not breastfeed during treatment with ARAKODA and for 3 months after your last dose of ARAKODA. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. ARAKODA and other medicines may affect each other causing side effects. How should I take ARAKODA? • Take ARAKODA exactly as your healthcare provider tells you to take it. • ARAKODA is given as 2 tablets that you will take together as a single dose. Each ARAKODA tablet has 100 mg of tafenoquine. • You will start taking ARAKODA 3 days before you travel to a malaria area. o Take 2 tablets, 1 time each day for 3 days . • You will continue to take ARAKODA while you are in the malaria area. o Take 2 tablets, 1 time each week . o Start taking this dose of ARAKODA 7 days after the last dose of ARAKODA that you took before your travel to the malaria area. • You will take your last dose of ARAKODA after you leave the malaria area. o Take 2 tablets. o Take this dose of ARAKODA 7 days after the last dose of ARAKODA that you took while you were in the malaria area. • Take ARAKODA tablets whole. Do not break, crush, or chew the tablets before swallowing. • Take ARAKODA with food. • It is important that you take the full course of treatment with ARAKODA . Do not stop taking ARAKODA without first talking to your healthcare provider because the medicine may not work as well to prevent malaria. • If you miss 1 or 2 daily doses of ARAKODA before your travel to the malaria area: o 1 daily dose : take 2 tablets (missed dose), and then continue to take your daily dose of ARAKODA until you have taken a total of 3 daily doses before your travel to the malaria area. Start taking your weekly doses or ARAKODA 1 week after your last daily dose. o 2 daily doses : take 2 tablets (missed dose), 1 time each day for 2 days in a row (consecutive days) so that you have taken a total of 3 daily doses before your travel to the malaria area. Start taking your weekly doses of ARAKODA 1 week after your last daily dose. • If you miss any weekly doses of ARAKODA while you are in the malaria area: o 1 weekly dose : take 2 tablets, 1 time on any day up to the time of your next scheduled weekly dose. o 2 weekly doses : take 2 tablets, 1 time on any day before your next scheduled weekly dose. o 3 or more weekly doses : take 2 tablets, 1 time each day for 2 days up to the time of your next scheduled weekly dose. • If you miss taking your last dose of ARAKODA 7 days after the last dose of ARAKODA you took while you were in the malaria area, take this last dose of ARAKODA as soon as you remember. What are the possible side effects of ARAKODA? ARAKODA may cause serious side effects, including : • See “ What is the most important information I should know about ARAKODA? ” • Allergic (hypersensitivity) reactions . See “ Do not take ARAKODA if you :” Allergic reactions can happen after you take ARAKODA. Signs and symptoms of an allergic reaction may not happen right away (delayed reaction). Get medical help right away if you have any signs or symptoms of an allergic reaction including: o swelling of the face, lips, tongue or throat o itching o trouble breathing or wheezing o vomiting o fainting and feeling lightheaded o rash o hives The most common side effects of ARAKODA include : diarrhea, headache, back pain, nausea, vomiting, dizziness, increased liver enzyme levels in your blood, motion sickness, insomnia, depression, abnormal dreams and anxiety. Other side effects of ARAKODA include eye problems . Some people who take ARAKODA can have a problem with the cornea of the eye called vortex keratopathy. This problem can be seen during an eye exam. Vortex keratopathy does not cause vision problems and will usually go away after you stop taking ARAKODA. These are not all the possible side effects of ARAKODA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Sixty Degrees Pharmaceuticals, LLC at 1-888-834-0225. How should I store ARAKODA? • Store ARAKODA at room temperature between 68°F to 77°F (20°C to 25°C). • Protect tablets from moisture. Keep ARAKODA and all medicines out of the reach of children . General information about the safe and effective use of ARAKODA. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ARAKODA for a condition for which it was not prescribed. Do not give ARAKODA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ARAKODA that is written for health professionals. What are the ingredients in ARAKODA? Active ingredient : tafenoquine succinate Inactive ingredients : microcrystalline cellulose, mannitol, and magnesium stearate. The tablet film-coating contains the following inactive ingredients: hypromellose, iron oxide red, titanium dioxide, and macrogol/polyethylene glycol. Manufactured for: Sixty Degrees Pharmaceuticals, LLC Washington, DC 20036 For more information, go to https://60degreespharma.com or call 1-888-834-0225. This Medication Guide has been approved by the U.S. Food and Drug Administration Issued: August 2018 Company Logo"],"geriatric_use":["8.5 Geriatric Use Clinical trials of ARAKODA did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients [see Clinical Pharmacology ( 12.3 )] ."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness of ARAKODA in pediatric patients have not been established."],"effective_time":"20250110","clinical_studies":["14 CLINICAL STUDIES Clinical Trials 1, 2, and 3 Three double-blind, randomized, controlled studies have been performed to evaluate the efficacy of ARAKODA. Trial 1 (NCT #02491606) was a Phase IIb, placebo-controlled study conducted in Kenya, an area of holoendemic P. falciparum malaria. After taking a three-day presumptive course of halofantrine to eliminate any existing parasitemia, subjects were randomized into one of four groups (placebo and three different ARAKODA dosing groups; one group received 200 mg once daily for 3 days, then a maintenance regimen of weekly dose of 200 mg for 10-15 weeks). Sixty-one percent of subjects were male. The mean age was 32.4 years (range 17-55). Subjects were evaluated for parasitemia by weekly blood smears. Protective efficacy at 15 weeks was defined based on the reduced incidence of parasitemia during the prophylaxis phase relative to placebo. The results in the intention-to-treat population, which included all subjects who received three doses of halofantrine and were randomized, are shown in Table 6 below. Table 6: Incidence of Parasitemia and Protective Efficacy of ARAKODA at 15 weeks for Trial 1 Placebo ARAKODA 1 1 200 mg once daily for 3 days, then 200 mg weekly for 10-15 weeks 2 Protective efficacy is reduced incidence of parasitemia relative to placebo (0: no protection; 1: full protection); CI: confidence interval. Bonferroni adjustment was used for multiple comparisons. Missing outcome was considered a failure due to parasitemia for this analysis. Number of subjects 62 61 Subjects free of parasitemia 5 (8.1%) 46 (75.4) Subjects with parasitemia 54 (87.1%) 7 (11.5%) Subjects with missing data 3 (4.8%) 8 (13.1%) Protective efficacy [98.3% CI] 2 – 73.3% [54.0%, 84.5%] Trial 2 (NCT #02488902) was a comparison of tafenoquine to placebo for prophylaxis in healthy semi-immune residents of a malarious region in Ghana. After treating existing parasitemia with quinine/doxycycline/primaquine, subjects were randomized into prophylactic groups including ARAKODA and placebo. Patients were administered a loading regimen of daily drug or placebo for 3 days followed by a maintenance regimen of weekly drug or placebo for 12 weeks. For the ARAKODA and placebo groups, males were 65% of the total population. The mean age was 38.4 years and 53.5 years for males and females, respectively, as women in reproductive ages were excluded from the study. The mean weight was 55.4 kg and 47.5 kg for males and females, respectively. Subjects were evaluated for parasitemia by weekly blood smears. Parasitemia required a blood smear positive for asexual stage of P. falciparum . The incidence of parasitemia at week 12 for all randomized subjects who received at least one dose of ARAKODA or placebo is presented in Table 7 below. Table 7: Incidence of Parasitemia and Protective Efficacy of ARAKODA at Week 12 for Trial 2 Placebo ARAKODA 1 1 200 mg once daily for 3 days, then 200 mg weekly for 12 weeks 2 Protective efficacy is reduced incidence of parasitemia relative to placebo; CI: confidence interval. Bonferroni adjustment was used for multiple comparisons. Missing outcome was considered a failure due to parasitemia for this analysis. Number of subjects 94 93 Subjects free of parasitemia 6 (6.4%) 68 (73.1%) Subjects with parasitemia 86 (91.5%) 12 (12.9%) Subjects with missing data 2 (2.1%) 13 (14.0%) Protective efficacy [98.75% CI] 2 – 71.3% [55.8%, 81.4%] Trial 3 compared ARAKODA with mefloquine for the prophylaxis of both P. falciparum and P. vivax malaria in healthy non-immune soldiers deployed to East Timor (now Timor-Leste). No subject developed malaria during the 26-week prophylactic phase. Subjects were exposed to P. vivax and there is a high likelihood that the study subjects were also exposed to P. falciparum . Since the precise degree of exposure to malaria in study subjects is unknown, this study provides only supportive evidence of efficacy. Clinical Trial 7 In a randomized, double-blind, placebo-controlled trial (Trial 7) in healthy, non-immune volunteers, ARAKODA was shown to have prophylactic activity directed against blood-stage P. falciparum parasites. Twelve subjects received ARAKODA (200 mg once daily for 3 days, then 200 mg on 10 day) and 4 subjects received placebo. On Day 13, subjects were inoculated with erythrocytes containing viable P. falciparum parasites. Fifteen subjects (93.8%) were of white race. The mean age was 27.5 years (range 20-42). The mean body weight was 72.3 kg (range 56-97.7). The efficacy endpoint was parasitemia by Day 34; parasitemia was based on detection of P. falciparum 18S ribosomal DNA by real time polymerase chain reaction assay (PCR). There was a statistically significant difference in malaria incidence between the two groups; 4/4 (100%) subjects in the placebo group had detectable parasites from Day 17 compared to 0/12 (0%) subjects on ARAKODA were PCR negative at all visits (p<0.0005)."],"pharmacodynamics":["12.2 Pharmacodynamics Cardiac Electrophysiology The effect of tafenoquine on the QT interval was evaluated in a study of healthy adult subjects. In this study, subjects received once daily 400 mg (2 times the approved recommended dosage) doses of tafenoquine for 3 days. The results suggest that the mean increase in the QTcF interval for tafenoquine is less than 20 msec."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption A food effect study was not conducted with the 100 mg ARAKODA tablet. In majority of the clinical trials, tafenoquine was administered under fed conditions. Table 5 provides the pharmacokinetics of tafenoquine following single dose administration of 200 mg ARAKODA (two 100-mg ARAKODA tablets) in 65 healthy adult subjects under fed conditions. In this study, ARAKODA was administered with a high-calorie, high-fat meal (approximately 1000 calories with 19% protein, 31% carbohydrate, and 50% fat). Table 5. Mean (%CV) Pharmacokinetic Parameters of Tafenoquine Following Single Oral Administration of Two 100-mg ARAKODA Tablets Under Fed Conditions in Healthy Adult Subjects (N=65) Parameter Value a Coefficient of Variance (CV) b Median and (Range) c Plasma tafenoquine AUC inf increased by 41% when tafenoquine was administered as an investigational capsule formulation with a high-calorie, high-fat meal compared with the fasted state. C max 147 ng/mL (20.7%) a T max 14 hr (6 – 72 hr) b AUC inf 70 hr*mcg/mL (24.6%) a, c Following administration of a single dose of tafenoquine orally under fasted conditions in healthy adult subjects, AUC and C max increased dose proportionally over the dose range from 100 mg to 400 mg. When healthy adult subjects received once-weekly administrations of 200 mg tafenoquine orally for ten weeks without a loading dose under fasting conditions, the mean plasma accumulation ratio of tafenoquine was approximately 4.4. Distribution Tafenoquine is greater than 99.5% bound to protein in humans. The apparent volume of distribution of tafenoquine in healthy adult subjects is 2470 L [Inter-Individual Variability (IIV): 24.1 %]. Elimination The apparent oral clearance of tafenoquine is approximately 4.2 L/hr (IIV: 23.6 %) in healthy adult subjects. The mean terminal half-life following administration of ARAKODA is approximately 16.5 days (range: 10.8 days to 27.3 days) in healthy adult subjects. Metabolism Negligible metabolism of tafenoquine was observed in vitro in human liver microsomes and hepatocytes. Following administration of tafenoquine orally, once daily for three days to healthy adult subjects, unchanged tafenoquine represented the only notable drug-related component in plasma at approximately 3 days following the first dose of tafenoquine. Excretion The full excretion profile of tafenoquine in humans is unknown. Specific Populations The pharmacokinetics of tafenoquine were not significantly impacted by age, sex, ethnicity, and body weight. The effect of renal or hepatic impairment on tafenoquine pharmacokinetics is unknown. Drug Interaction Studies Clinical Studies No clinically significant effects on the pharmacokinetics of substrates of cytochrome P450 isoenzymes (CYP)1A2 (caffeine), CYP2D6 (desipramine), CYP2C9 (flurbiprofen), or CYP3A4 (midazolam) were observed following coadministration with tafenoquine in healthy adult subjects. In Vitro Studies Where Drug Interaction Potential Was Not Further Evaluated Clinically Tafenoquine inhibited metformin transport via human OCT2, MATE1 and MATE2-K transporters [see Drug Interactions ( 7 )] . Tafenoquine is not an inhibitor of human breast cancer resistance protein (BCRP), P-glycoprotein (P-gp), Organic anion transporter 1/3 (OAT1 or OAT3), Organic anion transporting polypeptide 1B1/1B3 (OATP1B1 or OATP1B3) mediated transport at clinically relevant concentrations. Tafenoquine is also not a substrate of human OATP1B1 or OATP1B3 at clinically relevant concentrations. It is inconclusive as to whether tafenoquine is a substrate of P-gp and/or BCRP mediated transport."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions observed with ARAKODA are discussed in detail in the Warnings and Precautions section: • Hemolytic Anemia [see Warnings and Precautions ( 5.2 )] • Methemoglobinemia [see Warnings and Precautions ( 5.3 )] • Psychiatric Effects [see Warnings and Precautions ( 5.4 )] • Hypersensitivity Reactions [see Warnings and Precautions ( 5.5 )] The most common adverse reactions (incidence ≥1%) were: headache, dizziness, back pain, diarrhea, nausea, vomiting, increased alanine aminotransferase (ALT), motion sickness, insomnia, depression, abnormal dreams, anxiety. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact 60 Degrees Pharmaceuticals at 1-888-834-0225 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of tafenoquine was studied in clinical trials at various doses and regimens in 3,184 subjects. The recommended ARAKODA regimen was evaluated in 825 subjects in 5 controlled clinical trials (Trials 1, Trial 2, Trial 3, Trial 4 and Trial 5). The mean duration of exposure to ARAKODA in these five clinical trials was 21 weeks (range 10-29 weeks). Trial 1, 2 and 4 were conducted in healthy semi-immune volunteers in Ghana or Kenya and were placebo-controlled; a mefloquine arm was included in Trials 2 and 4 as a benchmark. Trial 3, an active comparator (mefloquine) controlled trial was conducted in healthy soldiers deployed in East Timor (Timor Leste). A placebo-controlled Trial 5 was conducted in healthy volunteers in the United States and United Kingdom. The mean age of the subjects included in the five trials was 29 years (range 17 to 69 years); 84% were male. Adverse Reactions Reported with ARAKODA in Trial 3 and Pooled Trials 1, 2, 4, and 5 Adverse reactions occurring in ≥1% of subjects in the ARAKODA group in the placebo-controlled pooled Trials 1, 2, 3, and 4 are presented in Table 3 . Table 3: Selected Adverse Reactions Occurring in ≥1% of Subjects Receiving ARAKODA in Pooled Trials 1, 2, 4, and 5 (Non-Deployed Subjects) Adverse Reaction ARAKODA 1 (n=333) % Placebo (n=295) % Mefloquine 2 (n=147) % 1 ARAKODA was administered as 200 mg daily for 3 days, then 200 mg weekly 2 Mefloquine was administered as 250 mg daily for 3 days, then 250 mg weekly 3 Includes headache, sinus headache, migraine and tension headache. 4 Includes dizziness and dizziness postural 5 Includes abnormal dreams, insomnia, nightmares, sleep disorder, and somnambulism. Nervous system Disorders 35 34 47 Headache 3 32 32 44 Dizziness 4 5 3 10 Musculoskeletal and connective tissue disorders 27 26 37 Back pain 14 9 11 Gastrointestinal disorders 31 33 46 Diarrhea 5 3 1 Nausea 5 2 2 Vomiting 2 2 1 Investigations 8 7 11 Alanine Aminotransferase (ALT) increased/abnormal 4 2 3 Psychiatric disorders 2 1 2 Any sleep symptom 5 1 1 0 Insomnia 1 1 0 Depression/depressed mood 1 0 0 Adverse reactions occurring in ≥1% of subjects in the ARAKODA group in the active-control Trial 3 conducted in military personnel deployed to malaria endemic areas are presented in Table 4 . Table 4: Selected Adverse Reactions Occurring in ≥1% of Subjects Receiving ARAKODA in Trial 3 (Deployed Subjects) Adverse Reaction ARAKODA 1 (n=492) % Mefloquine 2 (n=162) % 1 ARAKODA was administered as 200 mg daily for 3 days, then 200 mg weekly 2 Mefloquine was administered as 250 mg daily for 3 days, then 250 mg weekly 3 Includes headache, sinus headache, migraine and tension headache. 4 Includes dizziness and dizziness postural 5 Includes motion sickness, vertigo and vertigo positional. 6 Includes abnormal dreams, insomnia, nightmares, sleep disorder, and somnambulism. 7 Includes abnormal dreams, nightmares 8 Includes anxiety disorder, panic attack and stress. Nervous system Disorders 22 27 Headache 3 15 19 Dizziness 4 1 1 Ear and labyrinth Disorders 7 11 Motion sicknesss 5 5 6 Musculoskeletal and connective tissue disorders 29 30 Back pain 14 15 Gastrointestinal disorders 36 41 Diarrhea 18 20 Nausea 7 9 Vomiting 5 6 Psychiatric disorders 5 4 Any sleep symptom 6 4 4 Insomnia 2 1 Abnormal dreams 7 2 2 Anxiety 8 1 0 Clinically Significant Adverse Reactions in Trials 1 to 5 (Overall Safety Population) Clinically significant adverse reactions with ARAKODA (200 mg daily for 3 days, followed by 200 mg weekly) in Trials 1 to 5 (n= 825) are described below: Ocular Adverse Reactions Vortex keratopathy was reported in 21% to 93% of subjects receiving ARAKODA in the trials which included ophthalmic evaluations (Trials 3, 5, and Trial 6 (NCT # 01290601, an active-control trial in patients from Thailand with P. vivax malaria. The keratopathy did not result in any apparent functional visual changes and resolved within one year after drug cessation in all patients. Retinal abnormalities were noted in less than 1% of subjects receiving ARAKODA. A total of 7 serious ocular adverse reactions (SARs) were reported in ARAKODA-treated subjects in the trials which included ophthalmic evaluations: 5 reports of keratopathy and two reports of retinal disorders. Laboratory Abnormalities Methemoglobinemia: Asymptomatic methemoglobin elevations were observed in 13% of subjects receiving ARAKODA. Hemoglobin decrease: Hemoglobin decreases of ≥ 3 g/dL were observed in 2.3% of subjects receiving ARAKODA. Adverse Reactions Reported in < 1% of Subjects Receiving ARAKODA in Trials 1 to 5 The following selected adverse reactions were reported in subjects receiving ARAKODA in Trials 1 to 5 at a rate of less than 1%. Blood and lymphatic system disorders: hemolytic anemia, anemia, thrombocytopenia Ear and labyrinth disorders: hyperacusis, Meniere’s disease Eye disorders: night blindness, photophobia, blurred vision, visual acuity reduced, visual impairment, vitreous floaters Hepatobiliary disorders: hyperbilirubinemia, jaundice cholestatic Immune system disorders: hypersensitivity Investigations: blood bilirubin increased, blood creatinine increased, glomerular filtration rate decreased Nervous system disorders: amnesia, coordination abnormal, hyperesthesia, hypoesthesia, somnolence, syncope, tremor, visual field defect Psychiatric disorders: agitation, neurosis Skin and subcutaneous tissue disorders: urticaria."],"contraindications":["4 CONTRAINDICATIONS ARAKODA is contraindicated in: • patients with G6PD deficiency or unknown G6PD status due to the risk of hemolytic anemia [see Warnings and Precautions ( 5.2 )] . • breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if the G6PD status of the infant is unknown [see Warnings and Precautions ( 5.3 ), Use in Specific Populations ( 8.2 )] . • patients with a history of psychotic disorders or current psychotic symptoms (i.e., hallucinations, delusions, and/or grossly disorganized behavior) [see Warnings and Precautions ( 5.4 )] • patients with known hypersensitivity reactions to tafenoquine, other 8-aminoquinolines, or any component of ARAKODA [see Warnings and Precautions ( 5.5 )] . • G6PD deficiency or unknown G6PD status ( 4 ) • Breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if G6PD status is unknown ( 4 , 8.2 ) • Patients with a history of psychotic disorders or current psychotic symptoms ( 4 , 5.4 ) • Known hypersensitivity reactions to tafenoquine, other 8-aminoquinolines, or any component of ARAKODA. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Avoid co-administration with drugs that are substrates of organic cation transporter-2 (OCT2) or multidrug and toxin extrusion (MATE) transporters ( 7.1 ) 7.1 Effect of ARAKODA on Organic Cation Transporter-2 (OCT2) and Multidrug and Toxin Extrusion (MATE) Substrates The effect of coadministration of tafenoquine on the pharmacokinetics of OCT2 and MATE substrates in humans is unknown. However, in vitro observations suggest the potential for increased concentrations of these substrates [see Clinical Pharmacology ( 12.3 )] which may increase the risk of toxicity of these drugs. Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin). If coadministration cannot be avoided, monitor for drug-related toxicities and consider dosage reduction if needed based on approved product labeling of the coadministered drug."],"spl_medguide_table":["Breakdown of red blood cells (hemolytic anemia). See “Do not take ARAKODA if you:” ARAKODA can cause a breakdown of red blood cells (hemolysis) in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Your healthcare provider will test you for G6PD deficiency before you start taking ARAKODA. Signs of hemolytic anemia may not happen right away (delayed reaction).Tell your healthcare provider or get emergency medical help right away if you develop signs of hemolytic anemia which include darkening of the urine, dizziness, confusion, feeling tired, light-headedness, or shortness of breath, pale skin or yellowing of the skin and whites of the eyes.Decrease of oxygen in your blood caused by a certain type of abnormal red blood cell (methemoglobinemia). Signs and symptoms of methemoglobinemia may not happen right away (delayed reaction). Get medical help right away if you have bluish coloring of the lips or skin, headache, fatigue, shortness of breath, or lack of energy.Mental health (psychiatric) symptoms. See “Do not take ARAKODA if you:” Sleep problems, depression, anxiety and psychosis have happened while taking ARAKODA. Psychiatric symptoms may not happen right away (delayed reaction). Get emergency medical help right away if you develop hallucinations (seeing or hearing things that are really not there), delusions (false or strange thoughts or beliefs), or if you get confused or have problems thinking while taking ARAKODA. Call your healthcare provider if you develop changes in your mood, anxiety, trouble sleeping (insomnia), or nightmares for 3 days or longer while taking ARAKODA.ARAKODA can have other serious side effects. See “What are the possible side effects of ARAKODA?”ARAKODA is a prescription medicine used to help prevent malaria in people 18 years of age and older. Malaria is a serious disease of the blood that is spread by infected mosquitos. It is not known if ARAKODA is safe and effective in children.have G6PD deficiency. are breastfeeding a child known to have G6PD deficiency or breastfeeding a child that has not been tested for G6PD deficiency.have a history of psychotic disorders, or you currently have psychotic symptoms including hallucinations (seeing or hearing things that are not really there), delusions (false or strange thoughts or beliefs), or disorganized thinking or behavior. are allergic to tafenoquine, other 8-aminoquinolines, or any of the ingredients in ARAKODA. See the end of this Medication Guide for a complete list of ingredients in ARAKODA.have nicotinamide adenine dinucleotide (NADH) reductase deficiency. People with NADH reductase deficiency have a higher risk for methemoglobinemia if they take ARAKODA. have or have had mental health problems. are pregnant or plan to become pregnant. ARAKODA can harm an unborn baby who has G6PD deficiency.You should not become pregnant during treatment with ARAKODA.Females who are able to become pregnant should use effective birth control (contraception) during treatment with ARAKODA. Talk with your healthcare provider about birth control methods that may be right for you.Your healthcare provider may suggest you take a pregnancy test before you start taking ARAKODA. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ARAKODA.are breastfeeding or plan to breastfeed. It is not known if ARAKODA passes into breast milk. See “Do not take ARAKODA if you:”Your healthcare provider should check your child for G6PD deficiency before you start breastfeeding.If you know your child has G6PD deficiency, do not breastfeed during treatment with ARAKODA and for 3 months after your last dose of ARAKODA.Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. ARAKODA and other medicines may affect each other causing side effects.Take ARAKODA exactly as your healthcare provider tells you to take it. ARAKODA is given as 2 tablets that you will take together as a single dose. Each ARAKODA tablet has 100 mg of tafenoquine.You will start taking ARAKODA 3 days before you travel to a malaria area.Take 2 tablets, 1 time each day for 3 days.You will continue to take ARAKODA while you are in the malaria area.Take 2 tablets, 1 time each week.Start taking this dose of ARAKODA 7 days after the last dose of ARAKODA that you took before your travel to the malaria area.You will take your last dose of ARAKODA after you leave the malaria area.Take 2 tablets.Take this dose of ARAKODA 7 days after the last dose of ARAKODA that you took while you were in the malaria area.Take ARAKODA tablets whole. Do not break, crush, or chew the tablets before swallowing.Take ARAKODA with food. It is important that you take the full course of treatment with ARAKODA. Do not stop taking ARAKODA without first talking to your healthcare provider because the medicine may not work as well to prevent malaria.If you miss 1 or 2 daily doses of ARAKODA before your travel to the malaria area:1 daily dose: take 2 tablets (missed dose), and then continue to take your daily dose of ARAKODA until you have taken a total of 3 daily doses before your travel to the malaria area. Start taking your weekly doses or ARAKODA 1 week after your last daily dose.2 daily doses: take 2 tablets (missed dose), 1 time each day for 2 days in a row (consecutive days) so that you have taken a total of 3 daily doses before your travel to the malaria area. Start taking your weekly doses of ARAKODA 1 week after your last daily dose.If you miss any weekly doses of ARAKODA while you are in the malaria area:1 weekly dose: take 2 tablets, 1 time on any day up to the time of your next scheduled weekly dose.2 weekly doses: take 2 tablets, 1 time on any day before your next scheduled weekly dose. 3 or more weekly doses: take 2 tablets, 1 time each day for 2 days up to the time of your next scheduled weekly dose. If you miss taking your last dose of ARAKODA 7 days after the last dose of ARAKODA you took while you were in the malaria area, take this last dose of ARAKODA as soon as you remember.See “What is the most important information I should know about ARAKODA?”Allergic (hypersensitivity) reactions. See “Do not take ARAKODA if you:” Allergic reactions can happen after you take ARAKODA. Signs and symptoms of an allergic reaction may not happen right away (delayed reaction). Get medical help right away if you have any signs or symptoms of an allergic reaction including:swelling of the face, lips, tongue or throatitchingtrouble breathing or wheezingvomitingfainting and feeling lightheadedrashhivesThe most common side effects of ARAKODA include: diarrhea, headache, back pain, nausea, vomiting, dizziness, increased liver enzyme levels in your blood, motion sickness, insomnia, depression, abnormal dreams and anxiety.Other side effects of ARAKODA include eye problems. Some people who take ARAKODA can have a problem with the cornea of the eye called vortex keratopathy. This problem can be seen during an eye exam. Vortex keratopathy does not cause vision problems and will usually go away after you stop taking ARAKODA.These are not all the possible side effects of ARAKODA.Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Sixty Degrees Pharmaceuticals, LLC at 1-888-834-0225.Store ARAKODA at room temperature between 68°F to 77°F (20°C to 25°C). Protect tablets from moisture. Keep ARAKODA and all medicines out of the reach of children.
MEDICATION GUIDE ARAKODA (AIR-uh-KOH-duh) (tafenoquine) tablets, for oral use
What is the most important information I should know about ARAKODA?ARAKODA can cause serious side effects including:
••••
What is ARAKODA?
•••
Do not take ARAKODA if you:
••••
Before taking ARAKODA, tell your health care provider about all your medical conditions, including if you:
•••ooo•oo
How should I take ARAKODA?
•••o•oo•oo••••oo•ooo•
What are the possible side effects of ARAKODA?ARAKODA may cause serious side effects, including:
••ooooooo
How should I store ARAKODA?
••
General information about the safe and effective use of ARAKODA.Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ARAKODA for a condition for which it was not prescribed. Do not give ARAKODA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ARAKODA that is written for health professionals.
What are the ingredients in ARAKODA?Active ingredient: tafenoquine succinate Inactive ingredients: microcrystalline cellulose, mannitol, and magnesium stearate. The tablet film-coating contains the following inactive ingredients: hypromellose, iron oxide red, titanium dioxide, and macrogol/polyethylene glycol.
Manufactured for:Sixty Degrees Pharmaceuticals, LLCWashington, DC 20036For more information, go to https://60degreespharma.com or call 1-888-834-0225.
"],"mechanism_of_action":["12.1 Mechanism of Action Tafenoquine is an 8-aminoquinoline antimalarial drug [see Microbiology ( 12.4 )] ."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Tafenoquine is an 8-aminoquinoline antimalarial drug [see Microbiology ( 12.4 )] . 12.2 Pharmacodynamics Cardiac Electrophysiology The effect of tafenoquine on the QT interval was evaluated in a study of healthy adult subjects. In this study, subjects received once daily 400 mg (2 times the approved recommended dosage) doses of tafenoquine for 3 days. The results suggest that the mean increase in the QTcF interval for tafenoquine is less than 20 msec. 12.3 Pharmacokinetics Absorption A food effect study was not conducted with the 100 mg ARAKODA tablet. In majority of the clinical trials, tafenoquine was administered under fed conditions. Table 5 provides the pharmacokinetics of tafenoquine following single dose administration of 200 mg ARAKODA (two 100-mg ARAKODA tablets) in 65 healthy adult subjects under fed conditions. In this study, ARAKODA was administered with a high-calorie, high-fat meal (approximately 1000 calories with 19% protein, 31% carbohydrate, and 50% fat). Table 5. Mean (%CV) Pharmacokinetic Parameters of Tafenoquine Following Single Oral Administration of Two 100-mg ARAKODA Tablets Under Fed Conditions in Healthy Adult Subjects (N=65) Parameter Value a Coefficient of Variance (CV) b Median and (Range) c Plasma tafenoquine AUC inf increased by 41% when tafenoquine was administered as an investigational capsule formulation with a high-calorie, high-fat meal compared with the fasted state. C max 147 ng/mL (20.7%) a T max 14 hr (6 – 72 hr) b AUC inf 70 hr*mcg/mL (24.6%) a, c Following administration of a single dose of tafenoquine orally under fasted conditions in healthy adult subjects, AUC and C max increased dose proportionally over the dose range from 100 mg to 400 mg. When healthy adult subjects received once-weekly administrations of 200 mg tafenoquine orally for ten weeks without a loading dose under fasting conditions, the mean plasma accumulation ratio of tafenoquine was approximately 4.4. Distribution Tafenoquine is greater than 99.5% bound to protein in humans. The apparent volume of distribution of tafenoquine in healthy adult subjects is 2470 L [Inter-Individual Variability (IIV): 24.1 %]. Elimination The apparent oral clearance of tafenoquine is approximately 4.2 L/hr (IIV: 23.6 %) in healthy adult subjects. The mean terminal half-life following administration of ARAKODA is approximately 16.5 days (range: 10.8 days to 27.3 days) in healthy adult subjects. Metabolism Negligible metabolism of tafenoquine was observed in vitro in human liver microsomes and hepatocytes. Following administration of tafenoquine orally, once daily for three days to healthy adult subjects, unchanged tafenoquine represented the only notable drug-related component in plasma at approximately 3 days following the first dose of tafenoquine. Excretion The full excretion profile of tafenoquine in humans is unknown. Specific Populations The pharmacokinetics of tafenoquine were not significantly impacted by age, sex, ethnicity, and body weight. The effect of renal or hepatic impairment on tafenoquine pharmacokinetics is unknown. Drug Interaction Studies Clinical Studies No clinically significant effects on the pharmacokinetics of substrates of cytochrome P450 isoenzymes (CYP)1A2 (caffeine), CYP2D6 (desipramine), CYP2C9 (flurbiprofen), or CYP3A4 (midazolam) were observed following coadministration with tafenoquine in healthy adult subjects. In Vitro Studies Where Drug Interaction Potential Was Not Further Evaluated Clinically Tafenoquine inhibited metformin transport via human OCT2, MATE1 and MATE2-K transporters [see Drug Interactions ( 7 )] . Tafenoquine is not an inhibitor of human breast cancer resistance protein (BCRP), P-glycoprotein (P-gp), Organic anion transporter 1/3 (OAT1 or OAT3), Organic anion transporting polypeptide 1B1/1B3 (OATP1B1 or OATP1B3) mediated transport at clinically relevant concentrations. Tafenoquine is also not a substrate of human OATP1B1 or OATP1B3 at clinically relevant concentrations. It is inconclusive as to whether tafenoquine is a substrate of P-gp and/or BCRP mediated transport. 12.4 Microbiology Mechanism of Action Tafenoquine, an 8-aminoquinoline antimalarial, is active against all the stages of Plasmodium species that include the hypnozoite (dormant stage) in the liver. Studies in vitro with the erythrocytic forms of Plasmodium falciparum suggest that tafenoquine may exert its effect by inhibiting hematin polymerization and inducing apoptotic like death of the parasite. In addition to its effect on the parasite, tafenoquine causes red blood cell shrinkage in vitro. The molecular target of tafenoquine is not known. Antimicrobial activity Tafenoquine is active against pre-erythrocytic (liver) and erythrocytic (asexual) forms as well as gametocytes of Plasmodium species that include P. falciparum and P. vivax. The activity of tafenoquine against the pre-erythrocytic liver stages of the parasite, prevents the development of the erythrocytic forms of the parasite [see Clinical Studies ( 14 )] . Resistance A potential for development of resistance of Plasmodium species to tafenoquine was not evaluated. Studies with the erythrocytic forms of P. falciparum strains/isolates suggest a potential for cross-resistance with primaquine, an 8-aminoquinoline. Clinical relevance of such findings is not known."],"indications_and_usage":["1 INDICATIONS AND USAGE ARAKODA is indicated for the prophylaxis of malaria in patients aged 18 years and older. ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Hemolytic Anemia : G6PD testing must be performed before prescribing ARAKODA due to the risk of hemolytic anemia. Monitor patients for signs or symptoms of hemolysis. ( 5.1 ) • G6PD Deficiency in Pregnancy or Lactation : ARAKODA may cause fetal harm when administered to a pregnant woman with a G6PD-deficient fetus. ARAKODA is not recommended during pregnancy. A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to ARAKODA through breast milk. Check infant’s G6PD status before breastfeeding begins. ( 5.2 , 8.1 , 8.2 ) • Methemoglobinemia : Asymptomatic elevations in blood methemoglobin have been observed. Initiate appropriate therapy if signs or symptoms of methemoglobinemia occur. ( 5.3 ) • Psychiatric Effects : Serious psychotic adverse reactions have been observed in patients with a history of psychosis or schizophrenia, at doses different from the approved dose. If psychotic symptoms (hallucinations, delusions, or grossly disorganized thinking or behavior) occur, consider discontinuation of ARAKODA therapy and, evaluation by a mental health professional as soon as possible. ( 5.4 ) • Hypersensitivity Reactions : Serious hypersensitivity reactions have been observed with administration of ARAKODA. If hypersensitivity reactions occur, institute appropriate therapy. ( 5.5 ) • Delayed Adverse Reactions : Due to the long half-life of ARAKODA (approximately 17 days), psychiatric effects, hemolytic anemia, methemoglobinemia, and hypersensitivity reactions may be delayed in onset and/or duration. ( 5.6 , 12.3 ) 5.1 Hemolytic Anemia Due to the risk of hemolytic anemia in patients with G6PD deficiency, G6PD testing must be performed before prescribing ARAKODA [see Contraindications ( 4 )] . Due to the limitations with G6PD tests, physicians need to be aware of residual risk of hemolysis and adequate medical support and follow-up to manage hemolytic risk should be available. Treatment with ARAKODA is contraindicated in patients with G6PD deficiency or unknown G6PD status [see Contraindications ( 4 )] . In clinical trials, declines in hemoglobin levels were reported in some G6PD-normal patients [see Adverse Reactions ( 6.1 )] . Monitor patients for clinical signs or symptoms of hemolysis [see Warnings and Precautions ( 5.6 )] . Advise patients to discontinue ARAKODA and seek medical attention if signs of hemolysis occur. 5.2 G6PD Deficiency in Pregnancy and Lactation Potential Harm to the Fetus The use of ARAKODA during pregnancy may cause hemolytic anemia in a G6PD-deficient fetus. Even if a pregnant woman has normal levels of G6PD, the fetus could be G6PD deficient. Advise females of reproductive potential that treatment with ARAKODA during pregnancy is not recommended and to avoid pregnancy or use effective contraception during treatment and for 3 months after the last dose of ARAKODA. If a pregnancy is detected during ARAKODA use, discontinue ARAKODA as soon as possible and switch to an alternative prophylactic drug for malaria during pregnancy [see Use in Specific Populations ( 8.1 and 8.3 )] . Potential Harm to the Breastfeeding Infant A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to ARAKODA through breast milk. Infant G6PD status should be checked before breastfeeding begins. ARAKODA is contraindicated in breastfeeding women when the infant is found to be G6PD deficient or the G6PD status of the infant is unknown [see Contraindications ( 4 )] . Advise the woman with a G6PD-deficient infant or if the G6PD status of the infant is unknown not to breastfeed during treatment with ARAKODA and for 3 months after the final dose [see Use in Specific Populations ( 8.2 )] . 5.3 Methemoglobinemia Asymptomatic elevations in methemoglobin have been observed in the clinical trials of ARAKODA [see Adverse Reactions ( 6.1 )] . Institute appropriate therapy if signs or symptoms of methemoglobinemia occur [see Warnings and Precautions ( 5.6 )] . Carefully monitor individuals with nicotinamide adenine dinucleotide (NADH)-dependent methemoglobin reductase deficiency. Advise patients to discontinue ARAKODA and seek medical attention if signs of methemoglobinemia occur. 5.4 Psychiatric Effects In patients receiving ARAKODA in clinical trials, psychiatric adverse reactions included sleep disturbances (2.5%), depression/depressed mood (0.3%), and anxiety (0.2%) [see Adverse Reactions ( 6.1 )] . ARAKODA was discontinued in a subject with an adverse reaction of suicide attempt (0.1%). Subjects with a history of psychiatric disorders were excluded from three of five ARAKODA trials in which mefloquine was included as a comparator. Psychosis was reported in three patients with a history of psychosis or schizophrenia who received tafenoquine doses (350 mg to 500 mg single dose, or 400 mg daily for 3 days) different from the approved ARAKODA regimen. Safety and effectiveness of ARAKODA have not been established at doses or regimens other than the approved regimen; use of ARAKODA at doses or regimens other than a 200-mg weekly dose is not approved by FDA. ARAKODA is contraindicated in patients with a history of psychotic disorders or current psychotic symptoms [see Contraindication ( 4 )] . If psychotic symptoms (hallucinations, delusions, or grossly disorganized thinking or behavior) occur, consider discontinuation of ARAKODA and prompt evaluation by a mental health professional as soon as possible. Other psychiatric symptoms, such as changes in mood, anxiety, insomnia, and nightmares, should be promptly evaluated by a medical professional if they are moderate and last more than three days or are severe [see Warnings and Precautions ( 5.6 )] . 5.5 Hypersensitivity Reactions Serious hypersensitivity reactions (e.g., angioedema and urticaria) have been observed with administration of tafenoquine. Hypersensitivity reactions have been reported in clinical trials of ARAKODA [see Adverse Reactions ( 6.1 )] . Discontinue prophylaxis with ARAKODA and institute appropriate therapy if hypersensitivity reactions occur [see Warnings and Precautions ( 5.6 )] . ARAKODA is contraindicated in patients who develop hypersensitivity to tafenoquine or any component of ARAKODA or other 8-aminoquinolines [see Contraindications ( 4 )] . 5.6 Delayed Adverse Reactions, Including Hemolytic Anemia, Methemoglobinemia, Psychiatric Effects, and Hypersensitivity Reactions Adverse reactions including hemolytic anemia, methemoglobinemia, psychiatric effects, and hypersensitivity reactions were reported with the use of ARAKODA or tafenoquine in clinical trials [see Warnings and Precautions ( 5.1 , 5.3 , 5.4 , 5.5 )] . Due to the long half-life of ARAKODA (approximately 17 days), psychiatric effects, hemolytic anemia, methemoglobinemia, and signs or symptoms of hypersensitivity reactions that may occur could be delayed in onset and/or duration. Advise patients to seek medical attention if signs of hypersensitivity occur [see Clinical Pharmacology ( 12.3 )] ."],"clinical_studies_table":["
Table 6: Incidence of Parasitemia and Protective Efficacy of ARAKODA at 15 weeks for Trial 1
PlaceboARAKODA1
1 200 mg once daily for 3 days, then 200 mg weekly for 10-15 weeks 2 Protective efficacy is reduced incidence of parasitemia relative to placebo (0: no protection; 1: full protection); CI: confidence interval. Bonferroni adjustment was used for multiple comparisons. Missing outcome was considered a failure due to parasitemia for this analysis.
Number of subjects6261
Subjects free of parasitemia5 (8.1%)46 (75.4)
Subjects with parasitemia54 (87.1%)7 (11.5%)
Subjects with missing data3 (4.8%)8 (13.1%)
Protective efficacy [98.3% CI]2–73.3% [54.0%, 84.5%]
","
Table 7: Incidence of Parasitemia and Protective Efficacy of ARAKODA at Week 12 for Trial 2
PlaceboARAKODA1
1 200 mg once daily for 3 days, then 200 mg weekly for 12 weeks 2 Protective efficacy is reduced incidence of parasitemia relative to placebo; CI: confidence interval. Bonferroni adjustment was used for multiple comparisons. Missing outcome was considered a failure due to parasitemia for this analysis.
Number of subjects9493
Subjects free of parasitemia6 (6.4%)68 (73.1%)
Subjects with parasitemia 86 (91.5%)12 (12.9%)
Subjects with missing data2 (2.1%)13 (14.0%)
Protective efficacy [98.75% CI]2–71.3% [55.8%, 81.4%]
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Two-year oral carcinogenicity studies were conducted in rats and mice. Renal cell adenomas and carcinomas were increased in male rats at doses 1 mg/kg/day and above (0.5 times the clinical exposure based on AUC comparisons). Tafenoquine was not carcinogenic in mice. The relevance of these findings to a carcinogenic risk in humans is unclear. Mutagenesis Tafenoquine did not cause mutations or chromosomal damage in 2 definitive in vitro tests (bacterial mutation assay and mouse lymphoma L5178Y cell assay) or in an in vivo oral rat micronucleus test. Impairment of Fertility In a rat fertility study, tafenoquine was given orally at 1.5, 5, and 15 mg/kg/day (up to about 0.5 times the human dose based on body surface area comparisons) to males for at least 67 days, including 29 days prior to mating, and to females from 15 days prior to mating through early pregnancy. Tafenoquine resulted in reduced number of viable fetuses, implantation sites, and corpora lutea at 15 mg/kg in the presence of maternal toxicity (mortality, piloerection, rough coat, and reduced body weight)."],"pharmacokinetics_table":["
Table 5. Mean (%CV) Pharmacokinetic Parameters of Tafenoquine Following Single Oral Administration of Two 100-mg ARAKODA Tablets Under Fed Conditions in Healthy Adult Subjects (N=65)
ParameterValue
a Coefficient of Variance (CV) b Median and (Range) c Plasma tafenoquine AUCinf increased by 41% when tafenoquine was administered as an investigational capsule formulation with a high-calorie, high-fat meal compared with the fasted state.
Cmax147 ng/mL (20.7%)a
Tmax14 hr (6 – 72 hr)b
AUCinf70 hr*mcg/mL (24.6%)a, c
"],"adverse_reactions_table":["
Table 3: Selected Adverse Reactions Occurring in ≥1% of Subjects Receiving ARAKODA in Pooled Trials 1, 2, 4, and 5 (Non-Deployed Subjects)
Adverse ReactionARAKODA1 (n=333) %Placebo (n=295) %Mefloquine2 (n=147) %
1 ARAKODA was administered as 200 mg daily for 3 days, then 200 mg weekly 2 Mefloquine was administered as 250 mg daily for 3 days, then 250 mg weekly 3 Includes headache, sinus headache, migraine and tension headache. 4 Includes dizziness and dizziness postural 5 Includes abnormal dreams, insomnia, nightmares, sleep disorder, and somnambulism.
Nervous system Disorders353447
Headache3323244
Dizziness45310
Musculoskeletal and connective tissue disorders272637
Back pain14911
Gastrointestinal disorders313346
Diarrhea531
Nausea522
Vomiting221
Investigations8711
Alanine Aminotransferase (ALT) increased/abnormal423
Psychiatric disorders212
Any sleep symptom5110
Insomnia110
Depression/depressed mood100
","
Table 4: Selected Adverse Reactions Occurring in ≥1% of Subjects Receiving ARAKODA in Trial 3 (Deployed Subjects)
Adverse ReactionARAKODA1 (n=492) %Mefloquine2 (n=162) %
1 ARAKODA was administered as 200 mg daily for 3 days, then 200 mg weekly 2 Mefloquine was administered as 250 mg daily for 3 days, then 250 mg weekly 3 Includes headache, sinus headache, migraine and tension headache. 4 Includes dizziness and dizziness postural 5 Includes motion sickness, vertigo and vertigo positional. 6 Includes abnormal dreams, insomnia, nightmares, sleep disorder, and somnambulism. 7 Includes abnormal dreams, nightmares 8 Includes anxiety disorder, panic attack and stress.
Nervous system Disorders2227
Headache31519
Dizziness411
Ear and labyrinth Disorders711
Motion sicknesss556
Musculoskeletal and connective tissue disorders2930
Back pain1415
Gastrointestinal disorders3641
Diarrhea1820
Nausea79
Vomiting56
Psychiatric disorders54
Any sleep symptom644
Insomnia21
Abnormal dreams722
Anxiety810
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Medication Guide ). G6PD Testing and Hemolytic Anemia Inform patients of the need for testing for G6PD deficiency before starting ARAKODA. Advise patients on the symptoms of hemolytic anemia and instruct them to seek medical advice promptly if such symptoms occur. Patients should contact their health care provider if they have darker lips or urine as these may be signs of hemolysis or methemoglobinemia [see Warnings and Precautions ( 5.1 )] . Important Administration Instructions • Advise patients to take ARAKODA with food. • Advise patients to swallow the tablet whole and not to break, crush or chew it. • Advise patients to complete the full course of ARAKODA including the loading dose, maintenance dose and terminal dose. Potential Harm to the Fetus Advise females of reproductive potential of the potential risk of ARAKODA to a fetus and to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions ( 5.2 ) and Use in Specific Populations ( 8.1 )] . Advise females of reproductive potential to avoid pregnancy or use effective contraception during treatment with ARAKODA and for 3 months after the final dose [see Use in Specific Populations ( 8.3 )] . Lactation Advise women with a G6PD-deficient infant, or if they do not know the G6PD status of their infant, not to breastfeed during treatment with ARAKODA and for 3 months after the final dose [see Contraindication ( 4 ), Warnings and Precautions ( 5.2 ), Use in Specific Populations ( 8.2 )] . Methemoglobinemia Inform patients that methemoglobinemia has occurred with ARAKODA. Advise patients on the symptoms of methemoglobinemia and instruct them to seek medical advice promptly if such symptoms occur [see Warnings and Precautions ( 5.3 )] . Psychiatric Symptoms Advise patients who experience hallucinations, delusions, or confused thinking while taking ARAKODA to seek medical attention as soon as possible. Other psychiatric symptoms, such as changes in mood, anxiety, insomnia, and nightmares, should be promptly evaluated by a medical professional if they last more than three days or severe [see Warnings and Precautions ( 5.4 )] . Hypersensitivity Reactions Inform patients that hypersensitivity reactions have occurred with ARAKODA. Advise patients on the symptoms of hypersensitivity reactions and instruct them to seek medical advice promptly if such symptoms occur [see Warnings and Precautions ( 5.5 )] . Manufactured For: 60 Degrees Pharmaceuticals INC, 1025 Connecticut Avenue NW, Suite 1000, Washington DC 20036 1217a"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION • All patients must be tested for glucose-6-phosphate dehydrogenase (G6PD) deficiency prior to prescribing ARAKODA. ( 2.1 ) • Pregnancy testing is recommended for females of reproductive potential prior to initiating treatment with ARAKODA. ( 2.1 ) Regimen Name Timing Dosage Loading regimen For each of the 3 days before travel to a malarious area 200 mg (2 of the 100 mg tablets) once daily for 3 days Maintenance regimen While in the malarious area 200 mg (2 of the 100 mg tablets) once weekly – start 7 days after the last loading regimen dose Terminal prophylaxis regimen In the week following exit from the malarious area 200 mg (2 of the 100 mg tablets) one-time 7 days after the last maintenance dose • Administer ARAKODA with food. ( 2.2 ) • See full prescribing information for instructions on how to replace missed doses. ( 2.2 ) 2.1 Tests to be Performed Prior to ARAKODA Dose Initiation All patients must be tested for glucose-6-phosphate dehydrogenase (G6PD) deficiency prior to prescribing ARAKODA [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 )] . Pregnancy testing is recommended for females of reproductive potential prior to initiating treatment with ARAKODA [see Use in Specific Populations ( 8.1 and 8.3 )] . 2.2 Recommended Dosage and Administration Instructions The recommended dosage of ARAKODA is described in Table 1 below. ARAKODA can be administered for up to 6 months of continuous dosing. Table 1: Recommended Dosage of ARAKODA in Patients (18 Years of Age and Older) Regimen Name Timing Dosage Loading regimen For each of the 3 days before travel to a malarious area 200 mg (2 of the 100 mg tablets) once daily for 3 days Maintenance regimen While in the malarious area 200 mg (2 of the 100 mg tablets) once weekly – start 7 days after the last loading regimen dose Terminal prophylaxis regimen In the week following exit from the malarious area 200 mg (2 of the 100 mg tablets) taken one time, 7 days after the last maintenance dose • Administer ARAKODA with food. [see Clinical Pharmacology ( 12.3 )] . • Swallow the tablet whole. Do not break, crush or chew the tablets. • Complete the full course of ARAKODA including the loading dose and the terminal dose. Table 2: How to Replace Missed Doses of ARAKODA Dose(s) Missed How to Replace Missed Dose(s): 1 Loading dose 1 dose of 200 mg (2 of the 100 mg tablets) so that a total of 3 daily loading doses have been taken. Begin maintenance dose 1 week after the last loading dose. 2 Loading doses 2 doses of 200 mg (2 of the 100 mg tablets) on 2 consecutive days so that a total of 3 daily loading doses have been taken. Begin maintenance dose 1 week after the last loading dose. 1 Maintenance (weekly) dose 1 dose of 200 mg (2 of the 100 mg tablets) on any day up to the time of the next scheduled weekly dose. 2 Maintenance (weekly) doses 1 dose of 200 mg (2 of the 100 mg tablets) on any day up to the time of the next scheduled weekly dose. 3 or more Maintenance (weekly) doses 2 doses of 200 mg (2 of the 100 mg tablets), taken as 200 mg (2 of the 100 mg tablets) once daily for 2 days up to the time of the next weekly dose. Terminal prophylaxis dose 1 dose of 200 mg (2 of the 100 mg tablets) as soon as remembered."],"spl_product_data_elements":["Arakoda Tafenoquine TAFENOQUINE TAFENOQUINE MAGNESIUM STEARATE MANNITOL MICROCRYSTALLINE CELLULOSE HYPROMELLOSE, UNSPECIFIED FERRIC OXIDE RED POLYETHYLENE GLYCOL, UNSPECIFIED TITANIUM DIOXIDE Dark TQ100"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS ARAKODA tablets are dark pink, film-coated, capsule-shaped tablets debossed with ‘TQ100’ on one side containing 100 mg of tafenoquine. Tablets: 100 mg of tafenoquine ( 3 )"],"clinical_pharmacology_table":["
Table 5. Mean (%CV) Pharmacokinetic Parameters of Tafenoquine Following Single Oral Administration of Two 100-mg ARAKODA Tablets Under Fed Conditions in Healthy Adult Subjects (N=65)
ParameterValue
a Coefficient of Variance (CV) b Median and (Range) c Plasma tafenoquine AUCinf increased by 41% when tafenoquine was administered as an investigational capsule formulation with a high-calorie, high-fat meal compared with the fasted state.
Cmax147 ng/mL (20.7%)a
Tmax14 hr (6 – 72 hr)b
AUCinf70 hr*mcg/mL (24.6%)a, c
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation : Advise women not to breastfeed a G6PD-deficient infant or infant with unknown G6PD status during treatment and for 3 months after the last dose of ARAKODA. ( 5.2 , 8.2 ) 8.1 Pregnancy Risk Summary The use of ARAKODA during pregnancy may cause hemolytic anemia in a fetus who is G6PD-deficient. Treatment with ARAKODA during pregnancy is not recommended. If a pregnancy is detected during ARAKODA use, discontinue ARAKODA as soon as possible and switch to an alternative prophylactic drug for malaria during pregnancy [see Warnings and Precautions ( 5.2 )] . Available data with use of ARAKODA in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal studies, there were increased abortions, with and without maternal toxicity when tafenoquine was given orally to pregnant rabbits at and above doses equivalent to about 0.4 times the clinical exposure based on body surface area comparisons. No fetotoxicity was observed at doses about 1.5 times the clinical exposure (based on body surface area comparisons) in a similar study in rats. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk: Malaria during pregnancy increases the risk for adverse pregnancy outcomes, including maternal anemia, prematurity, spontaneous abortion and stillbirth. Data Animal Data: Tafenoquine resulted in dose-related abortions when given orally to pregnant rabbits during organogenesis (Gestation Days 6 to 18), at doses of 7 mg/kg (about 0.4 times the clinical exposure based on body surface area comparisons) and above. Doses higher than 7 mg/kg were also associated with maternal toxicity (mortality and reduced body weight gain). In a similar study in rats, doses of 3, 10, or 30 mg/kg/day resulted in maternal toxicity (enlarged spleen, reduced body weight and reduced food intake) but no fetotoxicity at the high dose (about 1.5 times the clinical exposure based on body surface area comparisons). There was no evidence of malformations in either species. In a pre- and postnatal development study in rats, tafenoquine administered throughout pregnancy and lactation produced maternal toxicity and a reversible decrease in offspring body weight gain and decrease in motor activity at 18 mg/kg/day, which is equivalent to about 0.6 times the clinical dose based on body surface area comparisons. 8.2 Lactation Risk Summary A breastfed infant with G6PD deficiency is at risk for hemolytic anemia from exposure to ARAKODA. Infant G6PD status should be checked before breastfeeding begins. ARAKODA is contraindicated in breastfeeding women when the infant is found to be G6PD deficient or the G6PD status of the infant is unknown [see Contraindications ( 4 ) and Clinical Considerations ] . There is no information regarding the presence of ARAKODA in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. In a breastfed infant with normal G6PD, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ARAKODA and any potential effects on the breastfed infant from ARAKODA or from the underlying maternal condition. Clinical Considerations Check the infant’s G6PD status before maternal breastfeeding commences. If an infant is G6PD-deficient, exposure to ARAKODA during breastfeeding may result in hemolytic anemia in the infant; therefore, advise the woman with an infant who has G6PD deficiency or whose G6PD status is unknown, not to breastfeed during treatment with ARAKODA and for 3 months after the final dose of ARAKODA. 8.3 Females and Males of Reproductive Potential Pregnancy Testing Verify the pregnancy status in females of reproductive potential prior to initiating treatment with ARAKODA. [see Dosage and Administration ( 2.2 ), Warnings and Precautions, ( 5.2 ), and Use in Specific Populations ( 8.1 )] . Contraception ARAKODA may cause hemolytic anemia in a G6PD-deficient fetus [see Warnings and Precautions ( 5.2 ), Use in Specific Populations ( 8.1 )] . Advise females of reproductive potential that treatment with ARAKODA during pregnancy is not recommended and to avoid pregnancy or use effective contraception for 3 months after the final dose of ARAKODA. 8.4 Pediatric Use Safety and effectiveness of ARAKODA in pediatric patients have not been established. 8.5 Geriatric Use Clinical trials of ARAKODA did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients [see Clinical Pharmacology ( 12.3 )] . 8.6 Renal Impairment The pharmacokinetics of ARAKODA have not been studied in patients with renal impairment. If ARAKODA is administered to such patients, monitoring for adverse reactions associated with ARAKODA is needed [see Warnings and Precautions ( 5 ), Adverse Reactions ( 6 )] . 8.7 Hepatic Impairment The pharmacokinetics of ARAKODA have not been studied in patients with hepatic impairment. If ARAKODA is administered to such patients, monitoring for adverse reactions associated with ARAKODA is needed [see Warnings and Precautions ( 5 ), Adverse Reactions ( 6 )] ."],"dosage_and_administration_table":["
Regimen NameTimingDosage
Loading regimenFor each of the 3 days before travel to a malarious area200 mg (2 of the 100 mg tablets) once daily for 3 days
Maintenance regimenWhile in the malarious area200 mg (2 of the 100 mg tablets) once weekly – start 7 days after the last loading regimen dose
Terminal prophylaxis regimenIn the week following exit from the malarious area200 mg (2 of the 100 mg tablets) one-time 7 days after the last maintenance dose
","
Table 1: Recommended Dosage of ARAKODA in Patients (18 Years of Age and Older)
Regimen NameTimingDosage
Loading regimenFor each of the 3 days before travel to a malarious area200 mg (2 of the 100 mg tablets) once daily for 3 days
Maintenance regimenWhile in the malarious area200 mg (2 of the 100 mg tablets) once weekly – start 7 days after the last loading regimen dose
Terminal prophylaxis regimenIn the week following exit from the malarious area200 mg (2 of the 100 mg tablets) taken one time, 7 days after the last maintenance dose
","
Table 2: How to Replace Missed Doses of ARAKODA
Dose(s) MissedHow to Replace Missed Dose(s):
1 Loading dose1 dose of 200 mg (2 of the 100 mg tablets) so that a total of 3 daily loading doses have been taken. Begin maintenance dose 1 week after the last loading dose.
2 Loading doses2 doses of 200 mg (2 of the 100 mg tablets) on 2 consecutive days so that a total of 3 daily loading doses have been taken. Begin maintenance dose 1 week after the last loading dose.
1 Maintenance (weekly) dose 1 dose of 200 mg (2 of the 100 mg tablets) on any day up to the time of the next scheduled weekly dose.
2 Maintenance (weekly) doses1 dose of 200 mg (2 of the 100 mg tablets) on any day up to the time of the next scheduled weekly dose.
3 or more Maintenance (weekly) doses2 doses of 200 mg (2 of the 100 mg tablets), taken as 200 mg (2 of the 100 mg tablets) once daily for 2 days up to the time of the next weekly dose.
Terminal prophylaxis dose1 dose of 200 mg (2 of the 100 mg tablets) as soon as remembered.
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - Carton Label Rx only NDC: 71475-257-01 KEEP OUT OF REACH OF CHILDREN ATTENTION: Dispense the enclosed Medication Guide to each patient Arakoda ® (tafenoquine) tablets, for oral use 100 mg 16 (2 x 8) Unit Dose Tablets Sixty Degrees Pharma Each tablet contains 100 mg tafenoquine (equivalent to 125.5 mg tafenoquine succinate). Store below 30°C (86°F). Protect from moisture. Dispense only in the original carton. See Prescribing Information for Dosage and Administration information. Two blister packs are contained in each carton. Each blister pack contains eight 100 mg tablets of Arakoda ® (tafenoquine), for oral use. Manufactured for: 60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Ave., NW, Suite 1000 Washington DC 20036 Country of Origin: India Sixty Degrees Pharma Arakoda ® (tafenoquine) tablets, for oral use Principal Display Panel - Inner Carton Label Rx only NDC: 71475-257-01 KEEP OUT OF REACH OF CHILDREN ATTENTION: Dispense the enclosed Medication Guide to each patient Arakoda ® (tafenoquine) tablets, for oral use 100 mg 16 (2 x 8) Unit Dose Tablets Sixty Degrees Pharma Arakoda ® (tafenoquine) tablets, for oral use 100 mg Principal Display Panel - Blister Label CODE: MP/DRUGS/25/10/92 NDC: 71475-257-01 21541667 EM 15572 Sixty Degrees Pharma Arakoda ® (tafenoquine) tablets, for oral use 100 mg Exp: Lot: Principal Display Panel - Bottle Label Rx only NDC: 71475-257-02 KEEP OUT OF REACH OF CHILDREN ATTENTION: Dispense the attached Medication Guide to each patient Arakoda ® (tafenoquine) tablets, for oral use 100 mg 8 Tablets Sixty Degrees Pharma Each tablet contains 100 mg tafenoquine (equivalent to 125.5 mg tafenoquine succinate). Store below 30ºC (86ºF). Protect from moisture. See Prescribing Information for Dosage and Administration information. Manufactured for: 60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Ave., NW, Suite 1000 Washington DC 20036 Country of Origin: India Principal Display Panel - Carton Label Principal Display Panel - Bottle Label Principal Display Panel - Blister Label Principal Display Panel - Inner Carton Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Two-year oral carcinogenicity studies were conducted in rats and mice. Renal cell adenomas and carcinomas were increased in male rats at doses 1 mg/kg/day and above (0.5 times the clinical exposure based on AUC comparisons). Tafenoquine was not carcinogenic in mice. The relevance of these findings to a carcinogenic risk in humans is unclear. Mutagenesis Tafenoquine did not cause mutations or chromosomal damage in 2 definitive in vitro tests (bacterial mutation assay and mouse lymphoma L5178Y cell assay) or in an in vivo oral rat micronucleus test. Impairment of Fertility In a rat fertility study, tafenoquine was given orally at 1.5, 5, and 15 mg/kg/day (up to about 0.5 times the human dose based on body surface area comparisons) to males for at least 67 days, including 29 days prior to mating, and to females from 15 days prior to mating through early pregnancy. Tafenoquine resulted in reduced number of viable fetuses, implantation sites, and corpora lutea at 15 mg/kg in the presence of maternal toxicity (mortality, piloerection, rough coat, and reduced body weight)."]},"tags":[{"label":"tafenoquine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"P01BA07","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Active","category":"status"},{"label":"Malaria","category":"indication"},{"label":"60 Degrees Pharms","category":"company"},{"label":"Approved 2010s","category":"decade"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antimalarials","category":"pharmacology"},{"label":"Antiparasitic Agents","category":"pharmacology"},{"label":"Antiprotozoal Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"drugs that are substrates of organic cation transporter-2 (OCT2) or multidrug and toxin extrusion (MATE) transporters","severity":"major","mechanism":"Potential for increased concentrations of OCT2 and MATE substrates due to inhibition by tafenoquine","management":"Avoid coadministration. If coadministration cannot be avoided, monitor for drug-related toxicities and consider dosage reduction if needed based on approved product labeling of the coadministered drug.","clinicalEffect":"Increased risk of toxicity of these drugs"}],"commonSideEffects":[{"effect":"Dizziness","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Nausea","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Vomiting","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Headache","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Decreased Hemoglobin","drugRate":"25%","severity":"common","_validated":true},{"effect":"Anxiety","drugRate":"reported","severity":"unknown"},{"effect":"Somnolence","drugRate":"reported","severity":"unknown"},{"effect":"Increased blood creatinine","drugRate":"reported","severity":"unknown"},{"effect":"Increased blood methemoglobin","drugRate":"reported","severity":"unknown"},{"effect":"Increased alanine aminotransferase","drugRate":"reported","severity":"unknown"},{"effect":"Hypersensitivity reactions","drugRate":"reported","severity":"unknown"},{"effect":"Vortex keratopathy","drugRate":"reported","severity":"unknown"},{"effect":"Photophobia","drugRate":"reported","severity":"unknown"},{"effect":"Insomnia","drugRate":"reported","severity":"unknown"},{"effect":"Abnormal dreams","drugRate":"reported","severity":"unknown"},{"effect":"Angioedema","drugRate":"reported","severity":"unknown"},{"effect":"Urticaria","drugRate":"reported","severity":"unknown"}],"specialPopulations":{"Lactation":"A breastfed infant with G6PD deficiency is at risk for hemolytic anemia from exposure to KRINTAFEL. Infant G6PD status should be checked before breastfeeding begins. KRINTAFEL is contraindicated in breastfeeding women when the infant is found to be G6PD deficient or the G6PD status of the infant is unknown.","Pregnancy":"The use of KRINTAFEL during pregnancy may cause hemolytic anemia in fetus who is G6PD deficient. Treatment with KRINTAFEL during pregnancy is not recommended. Available data with use of KRINTAFEL in pregnant women are insufficient to establish drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.","Geriatric use":"Clinical trials of KRINTAFEL did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.","Paediatric use":"The safety and effectiveness of KRINTAFEL have been established in pediatric patients aged 16 years and older. Use of KRINTAFEL in these pediatric patients is supported by evidence from adequate and well-controlled studies of KRINTAFEL. Safety and effectiveness of KRINTAFEL in pediatric patients younger than 16 years have not been established."}},"trials":[],"aliases":[],"company":"60 Degrees Pharms","patents":[{"applNo":"N210607","source":"FDA Orange Book","status":"Active","expires":"Dec 2, 2035","useCode":"U-2582","territory":"US","drugProduct":false,"patentNumber":"10342791","drugSubstance":false},{"applNo":"N210607","source":"FDA Orange Book","status":"Active","expires":"Dec 2, 2035","useCode":"U-2582","territory":"US","drugProduct":false,"patentNumber":"11744828","drugSubstance":false},{"applNo":"N210607","source":"FDA Orange Book","status":"Active","expires":"Dec 2, 2035","useCode":"U-2582","territory":"US","drugProduct":false,"patentNumber":"10888558","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TAFENOQUINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:12:03.981833+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:12:01.882337+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T03:12:39.751763+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:12:09.407076+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TAFENOQUINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:12:09.852711+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:12:00.522303+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:12:32.714813+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:12:00.522334+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:12:27.353265+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2364635/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:12:10.598796+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA210607","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:12:00.522339+00:00"}},"allNames":"krintafel","offLabel":[],"synonyms":["arakoda","krintafel","tafenoquine succinate","tafenoquine"],"timeline":[{"date":"2018-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from GLAXOSMITHKLINE to 60 Degrees Pharms"},{"date":"2018-07-20","type":"positive","source":"DrugCentral","milestone":"FDA approval (Glaxosmithkline)"}],"aiSummary":"Tafenoquine (Krintafel), marketed by 60 Degrees Pharms, is a prophylactic treatment for malaria, positioned in a competitive landscape dominated by off-patent generics such as chloroquine, hydroxychloroquine, and primaquine. Its key strength lies in its unique mechanism of action, which targets the parasite's heme detoxification pathway, offering a distinct therapeutic approach compared to traditional antimalarials. The primary risk is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.","approvals":[{"date":"2018-07-20","orphan":true,"company":"GLAXOSMITHKLINE","regulator":"FDA"}],"brandName":"Krintafel","ecosystem":[{"indication":"Malaria","otherDrugs":[{"name":"pyrimethamine","slug":"pyrimethamine","company":"Amedra Pharms"},{"name":"quinidine","slug":"quinidine","company":"Lilly"}],"globalPrevalence":240000}],"mechanism":{"novelty":"Follow-on","modality":"Small Molecule","drugClass":"tafenoquine","explanation":"Tafenoquine is an 8-aminoquinoline antimalarial drug [see Microbiology (12.4)].","oneSentence":"Tafenoquine works by targeting the parasite's heme detoxification pathway, preventing the parasite from producing heme and ultimately leading to its death.","technicalDetail":"Tafenoquine inhibits the parasite's dihydroorotate dehydrogenase (DHODH) enzyme, disrupting its pyrimidine biosynthesis and ultimately leading to its death."},"commercial":{"launchDate":"2018","_launchSource":"DrugCentral (FDA 2018-07-20, GLAXOSMITHKLINE)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3578","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=TAFENOQUINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TAFENOQUINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:47:31.553021","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T03:12:39.752189+00:00","fieldsConflicting":4,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"chloroquine","drugSlug":"chloroquine","fdaApproval":"1949-10-31","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"hydroxychloroquine","drugSlug":"hydroxychloroquine","fdaApproval":"1955-04-18","genericCount":15,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"primaquine","drugSlug":"primaquine","fdaApproval":"1952-01-23","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"amodiaquine","drugSlug":"amodiaquine","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"tafenoquine","indications":{"approved":[{"id":"tafenoquine-malaria-prophylaxis","name":"Malaria Prophylaxis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients aged 18 years and older","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients aged 18 years and older","diagnosticRequired":null,"brandNameForIndication":"Krintafel"}],"offLabel":[],"pipeline":[]},"currentOwner":"60 Degrees Pharms","drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"chloroquine","brandName":"chloroquine","genericName":"chloroquine","approvalYear":"1949","relationship":"same-class"},{"drugId":"hydroxychloroquine","brandName":"hydroxychloroquine","genericName":"hydroxychloroquine","approvalYear":"1955","relationship":"same-class"},{"drugId":"primaquine","brandName":"primaquine","genericName":"primaquine","approvalYear":"1952","relationship":"same-class"},{"drugId":"amodiaquine","brandName":"amodiaquine","genericName":"amodiaquine","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05361486","phase":"","title":"Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2023-08-28","conditions":["Malaria, Vivax"],"enrollment":187,"completionDate":"2024-12-31"},{"nctId":"NCT07373743","phase":"EARLY_PHASE1","title":"Pharmacokinetic (PK) Study of Tafenoquine in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"State University of New York - Upstate Medical University","startDate":"2026-05","conditions":["Pharmacokinetic in Normal Population"],"enrollment":20,"completionDate":"2027-03"},{"nctId":"NCT07060794","phase":"PHASE4","title":"Tafenoquine and ACTs (TADORE- Plus)","status":"NOT_YET_RECRUITING","sponsor":"Menzies School of Health Research","startDate":"2026-06","conditions":["Vivax Malaria"],"enrollment":507,"completionDate":"2028-06"},{"nctId":"NCT07060404","phase":"PHASE2,PHASE3","title":"Postpartum 8-aminoquinoline Breast Milk Study","status":"NOT_YET_RECRUITING","sponsor":"Curtin University","startDate":"2026-04","conditions":["Drug Pharmacokinetics in Healthy Volunteers"],"enrollment":60,"completionDate":"2027-05"},{"nctId":"NCT07052162","phase":"PHASE4","title":"Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children","status":"RECRUITING","sponsor":"Curtin University","startDate":"2025-10-20","conditions":["Pharmacokinetics of Tafenoquine"],"enrollment":30,"completionDate":"2026-03"},{"nctId":"NCT07430592","phase":"PHASE2","title":"This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria","status":"NOT_YET_RECRUITING","sponsor":"R. Kiplin Guy","startDate":"2026-03-20","conditions":["Malaria","Malaria Vivax","Radical Cure"],"enrollment":104,"completionDate":"2028-11-20"},{"nctId":"NCT07403643","phase":"PHASE4","title":"Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria","status":"NOT_YET_RECRUITING","sponsor":"Curtin University","startDate":"2026-04","conditions":["Uncomplicated Malaria"],"enrollment":60,"completionDate":"2026-12"},{"nctId":"NCT06575647","phase":"PHASE4","title":"Vivax Elimination With Tafenoquine (VET) Study","status":"COMPLETED","sponsor":"Shoklo Malaria Research Unit","startDate":"2025-02-19","conditions":["Malaria","Malaria, Vivax","Plasmodium Vivax","Plasmodium Vivax Malaria"],"enrollment":1242,"completionDate":"2025-10-04"},{"nctId":"NCT06656351","phase":"PHASE2","title":"B-FREE Chronic Babesiosis Study","status":"RECRUITING","sponsor":"60 Degrees Pharmaceuticals LLC","startDate":"2025-11-18","conditions":["Chronic Babesiosis"],"enrollment":40,"completionDate":"2027-09"},{"nctId":"NCT06207370","phase":"PHASE2","title":"Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis","status":"RECRUITING","sponsor":"60 Degrees Pharmaceuticals LLC","startDate":"2024-06-17","conditions":["Babesiosis"],"enrollment":33,"completionDate":"2027-07-01"},{"nctId":"NCT06478641","phase":"","title":"Expanded Use in Persistent (B. Microti) Babesiosis","status":"AVAILABLE","sponsor":"60 Degrees Pharmaceuticals LLC","startDate":"","conditions":["Persistent Babesiosis"],"enrollment":0,"completionDate":""},{"nctId":"NCT05690841","phase":"PHASE3","title":"FocaL Mass Drug Administration for Vivax Malaria Elimination","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-10-14","conditions":["Plasmodium Vivax Malaria","Malaria"],"enrollment":7530,"completionDate":"2027-05-01"},{"nctId":"NCT06666491","phase":"PHASE3","title":"An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":["Malaria, Vivax"],"enrollment":300,"completionDate":"2026-05-25"},{"nctId":"NCT05540470","phase":"NA","title":"Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield","status":"COMPLETED","sponsor":"Centre Hospitalier de Cayenne","startDate":"2022-09-12","conditions":["Malaria, Vivax"],"enrollment":1991,"completionDate":"2025-04-25"},{"nctId":"NCT06148792","phase":"PHASE3","title":"A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria","status":"RECRUITING","sponsor":"Menzies School of Health Research","startDate":"2024-05-10","conditions":["Vivax Malaria"],"enrollment":1090,"completionDate":"2027-03-01"},{"nctId":"NCT05788094","phase":"PHASE4","title":"ACT vs CQ With Tafenoquine for P. Vivax Mono-infection","status":"RECRUITING","sponsor":"Shoklo Malaria Research Unit","startDate":"2023-06-26","conditions":["Malaria","Malaria, Vivax","Plasmodium Vivax Malaria"],"enrollment":606,"completionDate":"2026-08-31"},{"nctId":"NCT04704999","phase":"PHASE4","title":"Southeast Asia Dose Optimization of Tafenoquine","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2024-07-22","conditions":["Plasmodium Vivax Malaria"],"enrollment":700,"completionDate":"2028-02-07"},{"nctId":"NCT04533347","phase":"PHASE2","title":"Tafenoquine in Patients With Mild to Moderate COVID-19","status":"COMPLETED","sponsor":"60 Degrees Pharmaceuticals LLC","startDate":"2021-02-19","conditions":["COVID 19 Disease"],"enrollment":86,"completionDate":"2022-06-30"},{"nctId":"NCT04411836","phase":"PHASE3","title":"Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2021-04-25","conditions":["Vivax Malaria","Plasmodium Vivax","Malaria, Vivax","Malaria Relapse"],"enrollment":960,"completionDate":"2024-09-30"},{"nctId":"NCT04984759","phase":"PHASE4","title":"Tafenoquine and Primaquine in Colostrum and Breast Milk","status":"WITHDRAWN","sponsor":"University of Oxford","startDate":"2023-07-01","conditions":["Healthy Lactating Women"],"enrollment":0,"completionDate":"2025-06-30"},{"nctId":"NCT05753150","phase":"","title":"Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand","status":"COMPLETED","sponsor":"Dr. Prayuth Sudathip","startDate":"2022-05-23","conditions":["Malaria, Vivax","G6PD Deficiency"],"enrollment":187,"completionDate":"2023-10-01"},{"nctId":"NCT05947812","phase":"PHASE2","title":"A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression","status":"UNKNOWN","sponsor":"60P Australia Pty Ltd","startDate":"2023-08-01","conditions":["COVID 19 Disease","Mild to Moderate COVID 19 Disease","SARS-CoV-2","Infectious Disease","Severe Acute Respiratory Syndrome Coronavirus 2"],"enrollment":148,"completionDate":"2024-04-27"},{"nctId":"NCT05096702","phase":"","title":"Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil","status":"UNKNOWN","sponsor":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","startDate":"2021-09-09","conditions":["Malaria, Vivax","G6PD Deficiency"],"enrollment":16000,"completionDate":"2023-09-09"},{"nctId":"NCT04609098","phase":"PHASE2","title":"Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2020-10-29","conditions":["Malaria, Falciparum"],"enrollment":80,"completionDate":"2020-12-23"},{"nctId":"NCT05203744","phase":"PHASE4","title":"Escalating Monthly Doses of Tafenoquine in Healthy Volunteers","status":"UNKNOWN","sponsor":"Naval Medical Research Center","startDate":"2022-05-10","conditions":["Prophylaxis"],"enrollment":200,"completionDate":"2022-12-03"},{"nctId":"NCT05081089","phase":"PHASE2","title":"Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2021-10-12","conditions":["Malaria,Falciparum"],"enrollment":80,"completionDate":"2022-01-13"},{"nctId":"NCT03320174","phase":"PHASE2","title":"Long-Term Safety Study of Tafenoquine","status":"COMPLETED","sponsor":"60 Degrees Pharmaceuticals LLC","startDate":"2017-10-05","conditions":["Healthy Volunteers"],"enrollment":600,"completionDate":"2021-07-13"},{"nctId":"NCT02563496","phase":"PHASE2","title":"A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-02-06","conditions":["Malaria, Vivax"],"enrollment":60,"completionDate":"2020-02-17"},{"nctId":"NCT02802501","phase":"PHASE3","title":"Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-04-08","conditions":["Malaria, Vivax"],"enrollment":150,"completionDate":"2019-08-19"},{"nctId":"NCT02488902","phase":"PHASE2","title":"A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"1998-08","conditions":["Malaria"],"enrollment":521,"completionDate":"2003-03"},{"nctId":"NCT02491606","phase":"PHASE2","title":"Evaluation of Weekly Tafenoquine","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"1997-05","conditions":["Malaria"],"enrollment":249,"completionDate":"1998-09"},{"nctId":"NCT02216123","phase":"PHASE3","title":"Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-04-30","conditions":["Malaria, Vivax"],"enrollment":251,"completionDate":"2016-11-04"},{"nctId":"NCT01376167","phase":"PHASE2","title":"Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":true,"startDate":"2014-04-24","conditions":["Malaria, Vivax"],"enrollment":851,"completionDate":"2016-11-18"},{"nctId":"NCT02658435","phase":"PHASE1","title":"Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-02-02","conditions":["Malaria, Vivax"],"enrollment":486,"completionDate":"2017-09-14"},{"nctId":"NCT01290601","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults","status":"TERMINATED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2003-09-15","conditions":["Malaria","Plasmodium Vivax"],"enrollment":70,"completionDate":"2005-01-10"},{"nctId":"NCT02184637","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-07-31","conditions":["Malaria, Vivax"],"enrollment":120,"completionDate":"2015-04-08"},{"nctId":"NCT00871156","phase":"PHASE1","title":"Tafenoquine/Chloroquine DDI Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03-24","conditions":["Malaria"],"enrollment":68,"completionDate":"2009-08-26"},{"nctId":"NCT01928914","phase":"PHASE1","title":"Tafenoquine Thorough QTc Study in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-26","conditions":["Malaria, Vivax"],"enrollment":260,"completionDate":"2012-06-04"},{"nctId":"NCT01205178","phase":"PHASE1","title":"G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07-02","conditions":["Malaria"],"enrollment":192,"completionDate":"2013-04-01"},{"nctId":"NCT02488980","phase":"PHASE2","title":"An Evaluation of Weekly Tafenoquine","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2000-05","conditions":["Falciparum Parasitaemia"],"enrollment":306,"completionDate":"2003-03"},{"nctId":"NCT02751294","phase":"PHASE1","title":"A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-05","conditions":["Malaria, Vivax"],"enrollment":14,"completionDate":"2016-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT01376167"],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Arakoda"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Krintafel"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"286549","NDDF":"017662","UNII":"262P8GS9L9","CHEBI":"CHEBI:135752","VANDF":"4037963","INN_ID":"7835","RXNORM":"2054023","UMLSCUI":"C0903411","chemblId":"CHEMBL2364635","ChEMBL_ID":"CHEMBL298470","KEGG_DRUG":"D10490","DRUGBANK_ID":"DB06608","PDB_CHEM_ID":" H3F","PUBCHEM_CID":"115358","SNOMEDCT_US":"773181000","IUPHAR_LIGAND_ID":"9722","SECONDARY_CAS_RN":"106635-81-8","MESH_SUPPLEMENTAL_RECORD_UI":"C055852"},"formularyStatus":[],"originalProduct":{"form":"TABLET, FILM COATED","route":"ORAL","company":"GlaxoSmithKline LLC","brandName":"Krintafel","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2018-","companyName":"GSK","relationship":"Original Developer"},{"period":"present","companyName":"60 Degrees Pharms","relationship":"Current Owner"}],"pharmacokinetics":{"source":"FDA label","halfLife":"15 days"},"publicationCount":358,"therapeuticAreas":["Rare Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"P01BA07","allCodes":["P01BA07"]},"biosimilarFilings":[],"originalDeveloper":"Glaxosmithkline","recentPublications":[{"date":"2026","pmid":"41849481","title":"[Expansion of the use of technologies to reduce cases of malaria due to Plasmodium vivax in the Brazilian Amazon: a budget impact analysis].","journal":"Cadernos de saude publica"},{"date":"2025","pmid":"41737900","title":"Strategic resource allocation for malaria elimination in endemic settings: a systematic review of cost-effectiveness evidence.","journal":"Frontiers in public health"},{"date":"2026","pmid":"41717344","title":"Resolving haplotypes of the glucose-6-phosphate dehydrogenase gene using long-range polymerase chain reaction and Oxford Nanopore sequencing.","journal":"Biology methods & protocols"},{"date":"2026 Feb","pmid":"41696711","title":"Plasmodium falciparum field isolates drug susceptibility in Mali.","journal":"JAC-antimicrobial resistance"},{"date":"2026 Feb 11","pmid":"41690325","title":"Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial.","journal":"The Lancet. Infectious diseases"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"60 Degrees Pharms","companyId":"60-degrees-pharms","modality":"Small molecule","firstApprovalDate":"2018","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-07-20T00:00:00.000Z","mah":"GLAXOSMITHKLINE","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":7,"withResults":2},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T03:12:39.752189+00:00","fieldsConflicting":4,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}